SCHEDULE: Farallon Capital Reports Passive Stake in Tyra Biosciences

Farallon Capital Management and affiliated entities have filed a Schedule 13G, reporting a passive ownership stake in Tyra Biosciences, Inc.

Summary

• This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership of Tyra Biosciences, Inc. common stock.
• The reporting persons are Farallon Capital Management, L.L.C. and various affiliated investment partnerships and individuals.
• As of June 30, 2026, the reporting persons collectively beneficially owned 6,000 shares of Tyra Biosciences, Inc. common stock.
• This represents 0% of the class of securities outstanding.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a passive ownership stake without indicating active engagement or significant changes in holdings.

Negatives

• The filing indicates a very small, passive ownership stake (0%) in Tyra Biosciences, Inc., suggesting no significant influence or active investment strategy by Farallon Capital.

Risks

• The filing does not contain any forward-looking statements or specific risk factors related to Tyra Biosciences, Inc. itself, as it is a disclosure of ownership by an external entity.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Tyra Biosciences, Inc. It solely reports on the ownership status of the reporting persons.

Management Comments

• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors to report passive stakes. The minimal ownership percentage (0%) suggests this is not a significant strategic investment by Farallon Capital in Tyra Biosciences at this time.

Stakeholder Impact

• Shareholders: The filing indicates a minimal, passive ownership by a large investment firm, which is unlikely to significantly impact share price or corporate strategy in the short term.

Key Dates

Keywords

Tyra Biosciences, Farallon Capital, Schedule 13G, Beneficial Ownership, Investment Management, Passive Stake, Common Stock